Loading…
AstraZeneca Pharma India (ASTRAZEN)₹6,515+0.54%Pharmaceuticals
AstraZeneca Pharma India is compared with the 10 closest in size in Pharmaceuticals (229 companies in the industry). It has a P/E of 96.2 against a peer median of 36.8, and ROCE of 29.0% against a peer median of 17.1%, and latest-quarter sales growth of 29.8% against a peer median of 17.3%. By market cap it is #7 of 11 in this set.
As of · Peer set: 10 closest in size in Pharmaceuticals
| Company | M-cap (₹ Cr) | P/E | ROCE % | ROE % | Debt / equity | Div. yield % | Sales (₹ Cr) | Net profit (₹ Cr) | Qtr sales growth % | Qtr profit growth % | Compare |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Onesource Specialty Pharma | 18,607 | — | 1.0 | −1.1 | 0.26 | 0.0 | 1,423 | −74 | 37.2 | 469.8 | vs ASTRAZEN |
| Shilpa Medicare | 18,303 | 61.6 | 10.9 | 9.4 | 0.25 | 0.1 | 1,533 | 243 | 45.1 | 114.9 | vs ASTRAZEN |
| Alivus Life Sciences | 18,135 | 30.0 | 24.9 | 19.0 | 0.02 | 0.3 | 2,562 | 566 | 6.3 | 31.1 | vs ASTRAZEN |
| Pfizer | 17,905 | 24.4 | 24.0 | 18.0 | 0.02 | 1.9 | 2,522 | 722 | 8.2 | 6.4 | vs ASTRAZEN |
| Eris Lifesciences | 17,536 | 24.6 | 14.0 | 18.7 | 0.60 | 0.6 | 3,118 | 651 | 12.6 | 39.5 | vs ASTRAZEN |
| Cohance Lifesciences | 16,992 | 159.6 | 8.1 | 7.1 | 0.10 | 0.0 | 2,275 | 150 | −23.2 | −198.0 | vs ASTRAZEN |
| AstraZeneca Pharma India | 16,286 | 96.2 | 29.0 | 23.3 | 0.13 | 0.6 | 2,281 | 187 | 29.8 | −32.2 | — |
| CORONA Remedies | 15,541 | 74.9 | 33.0 | 29.5 | 0.22 | 0.4 | 1,403 | 185 | 22.3 | 15.3 | vs ASTRAZEN |
| Jubilant Pharmova | 15,359 | 43.7 | 8.9 | 6.6 | 0.51 | 0.5 | 8,307 | 398 | 17.3 | −45.1 | vs ASTRAZEN |
| Natco Pharma | 14,403 | 12.6 | 17.1 | 16.9 | 0.08 | 0.6 | 4,089 | 1,414 | −44.7 | −57.1 | vs ASTRAZEN |
| Marksans Pharma | 13,979 | 27.0 | 19.0 | 15.2 | 0.11 | 0.3 | 2,954 | 421 | 35.7 | 174.2 | vs ASTRAZEN |
| Peer median | 16,992 | 36.8 | 17.1 | 16.9 | 0.13 | 0.4 | 2,522 | 398 | 17.3 | 15.3 |
Listed companies closest to AstraZeneca Pharma India in Pharmaceuticals include Onesource Specialty Pharma, Shilpa Medicare, Alivus Life Sciences, Pfizer, Eris Lifesciences, Cohance Lifesciences, CORONA Remedies, Jubilant Pharmova.
Onesource Specialty Pharma, with a market cap of ₹18,607 Cr.
AstraZeneca Pharma India trades at a P/E of 96.2; the median of its peer set is 36.8. A P/E above or below the median is a description, not a judgement on value.
AstraZeneca Pharma India's return on capital employed is 29.0%, above the peer median of 17.1%.